Diethylcarbamazine Citrate
The citrate salt form of diethylcarbamazine, used in the treatment and prevention of filarial infections, most importantly lymphatic filariasis. This salt form is used in oral tablets and is the standard pharmaceutical preparation of the drug. The citrate salt improves stability and palatability of the medication.
分子量
391.4200 g/mol
TPSA
159.00 Ų
作用機序
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D構造
Cite this structure
Embed this structure
SMILES
CCN(CC)C(=O)N1CCN(C)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
InChI
InChI=1S/C10H21N3O.C6H8O7/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-9H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Molecular Formula
C16H29N3O8
HBD / HBA
4 / 9
回転可能結合数
7
重原子数
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
The citrate salt form of diethylcarbamazine, used in the treatment and prevention of filarial infections, most importantly lymphatic filariasis. This salt form is used in oral tablets and is the standard pharmaceutical preparation of the drug. The citrate salt improves stability and palatability of the medication.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Diethylcarbamazine Citrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL937. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 15432. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="diethylcarbamazine-citrate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/diethylcarbamazine-citrate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/diethylcarbamazine-citrate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/diethylcarbamazine-citrate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="diethylcarbamazine-citrate"></drugfyi-drug>